The phase 3 CLEAR trial showed that frontline therapy with pembrolizumab (Keytruda) plus lenvatinib (Lenvima) reduced the risk of death by 34% versus sunitinib (Sutent) in patients with advanced renal cell carcinoma.
In this video, Viktor Grünwald, MD, University Hospital Essen, Germany, discusses an analysis shared at the 2021 ASCO Annual Meeting which explored efficacy in the CLEAR trial according to selected subgroups, as well as the association between depth of response and overall survival. (J Clin Oncol 39, 2021 [suppl 15; abstr 4560])
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.